Please assess the completion status of the following clinical trial:

Trial Title: Effect of LAPS-Exendin on Body Weight in Obese Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
1. Inclusion Criteria:~   * Age: 18 years to 65 years~  * Genders: male and female~  * healthy obese population~  * non-diabetes~  * stable body weight for at least 3 months prior to screening~2. Exclusion Criteria~   * Pregnant or nursing (lactating) women~  * Drug-induced obesity~  * Diabetes mellitus (type 1, 2, and other)~  * Previous surgical treatment for obesity~  * Any known history of severe gastrointestinal (GI) disease or intolerance~  * Known history of pancreatitis with presence of raised serum amylase and lipase~  * History of suicide attempts or recent history (within 2 years prior to screening) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs), antipsychotics, and lithium.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- HM11260C (Type: EXPERIMENTAL): HM11260C 4 mg weekly sc injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo weekly sc injection
- HM11260C 6 mg/week (Type: EXPERIMENTAL): HM11260C 6 mg weekly sc injection
- HM11260C 6 mg/biweekly (Type: EXPERIMENTAL): HM11260C 6 mg biweekly sc injection
- HM11260C 8 mg/biweekly (Type: EXPERIMENTAL): HM11260C 8 mg biweekly sc injection

Based on this trial design, predict the completion outcome and termination type (if applicable).